Cargando…
Therapeutic Efficacy of Cintredekin Besudotox (IL13-PE38QQR) in Murine Lung Fibrosis Is Unaffected by Immunity to Pseudomonas aeruginosa Exotoxin A
BACKGROUND: We have previously explored a therapeutic strategy for specifically targeting the profibrotic activity of IL-13 during experimental pulmonary fibrosis using a fusion protein comprised of human IL-13 and a mutated form of Pseudomonas aeruginosa exotoxin A (IL13-PE) and observed that the i...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806906/ https://www.ncbi.nlm.nih.gov/pubmed/20090941 http://dx.doi.org/10.1371/journal.pone.0008721 |
_version_ | 1782176347992358912 |
---|---|
author | Rosada, Rogério S. Moreira, Ana P. Frantz, Fabiani G. Puri, Raj K. Rahman, Aquilur Standiford, Theodore J. Zárate-Bladés, Carlos R. Silva, Célio L. Hogaboam, Cory M. |
author_facet | Rosada, Rogério S. Moreira, Ana P. Frantz, Fabiani G. Puri, Raj K. Rahman, Aquilur Standiford, Theodore J. Zárate-Bladés, Carlos R. Silva, Célio L. Hogaboam, Cory M. |
author_sort | Rosada, Rogério S. |
collection | PubMed |
description | BACKGROUND: We have previously explored a therapeutic strategy for specifically targeting the profibrotic activity of IL-13 during experimental pulmonary fibrosis using a fusion protein comprised of human IL-13 and a mutated form of Pseudomonas aeruginosa exotoxin A (IL13-PE) and observed that the intranasal delivery of IL13-PE reduced bleomycin-induced pulmonary fibrosis through its elimination of IL-13-responsive cells in the lung. The aim of the present study was to determine whether the presence of an immune response to P. aeruginosa and/or its exotoxin A (PE) would diminish the anti-fibrotic properties of IL13-PE. METHODOLOGY/PRINCIPAL FINDINGS: Fourteen days after P. aeruginosa infection, C57BL/6 mice were injected with bleomycin via the intratracheal route. Other groups of mice received 4 doses of saline or IL13-PE by either intranasal or intraperitoneal application, and were challenged i.t. with bleomycin 28 days later. At day 21 after bleomycin, all mice received either saline vehicle or IL13-PE by the intranasal route and histopatological analyses of whole lung samples were performed at day 28 after bleomycin. Intrapulmonary P. aeruginosa infection promoted a neutralizing IgG2A and IgA antibody response in BALF and serum. Surprisingly, histological analysis showed that a prior P. aeruginosa infection attenuated the development of bleomycin-induced pulmonary fibrosis, which was modestly further attenuated by the intranasal administration of IL13-PE. Although prior intranasal administration of IL13-PE failed to elicit an antibody response, the systemic administration of IL13-PE induced a strong neutralizing antibody response. However, the prior systemic sensitization of mice with IL13-PE did not inhibit the anti-fibrotic effect of IL13-PE in fibrotic mice. CONCLUSIONS: Thus, IL13-PE therapy in pulmonary fibrosis works regardless of the presence of a humoral immune response to Pseudomonas exotoxin A. Interestingly, a prior infection with P. aeruginosa markedly attenuated the pulmonary fibrotic response suggesting that the immune elicitation by this pathogen exerts anti-fibrotic effects. |
format | Text |
id | pubmed-2806906 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-28069062010-01-21 Therapeutic Efficacy of Cintredekin Besudotox (IL13-PE38QQR) in Murine Lung Fibrosis Is Unaffected by Immunity to Pseudomonas aeruginosa Exotoxin A Rosada, Rogério S. Moreira, Ana P. Frantz, Fabiani G. Puri, Raj K. Rahman, Aquilur Standiford, Theodore J. Zárate-Bladés, Carlos R. Silva, Célio L. Hogaboam, Cory M. PLoS One Research Article BACKGROUND: We have previously explored a therapeutic strategy for specifically targeting the profibrotic activity of IL-13 during experimental pulmonary fibrosis using a fusion protein comprised of human IL-13 and a mutated form of Pseudomonas aeruginosa exotoxin A (IL13-PE) and observed that the intranasal delivery of IL13-PE reduced bleomycin-induced pulmonary fibrosis through its elimination of IL-13-responsive cells in the lung. The aim of the present study was to determine whether the presence of an immune response to P. aeruginosa and/or its exotoxin A (PE) would diminish the anti-fibrotic properties of IL13-PE. METHODOLOGY/PRINCIPAL FINDINGS: Fourteen days after P. aeruginosa infection, C57BL/6 mice were injected with bleomycin via the intratracheal route. Other groups of mice received 4 doses of saline or IL13-PE by either intranasal or intraperitoneal application, and were challenged i.t. with bleomycin 28 days later. At day 21 after bleomycin, all mice received either saline vehicle or IL13-PE by the intranasal route and histopatological analyses of whole lung samples were performed at day 28 after bleomycin. Intrapulmonary P. aeruginosa infection promoted a neutralizing IgG2A and IgA antibody response in BALF and serum. Surprisingly, histological analysis showed that a prior P. aeruginosa infection attenuated the development of bleomycin-induced pulmonary fibrosis, which was modestly further attenuated by the intranasal administration of IL13-PE. Although prior intranasal administration of IL13-PE failed to elicit an antibody response, the systemic administration of IL13-PE induced a strong neutralizing antibody response. However, the prior systemic sensitization of mice with IL13-PE did not inhibit the anti-fibrotic effect of IL13-PE in fibrotic mice. CONCLUSIONS: Thus, IL13-PE therapy in pulmonary fibrosis works regardless of the presence of a humoral immune response to Pseudomonas exotoxin A. Interestingly, a prior infection with P. aeruginosa markedly attenuated the pulmonary fibrotic response suggesting that the immune elicitation by this pathogen exerts anti-fibrotic effects. Public Library of Science 2010-01-15 /pmc/articles/PMC2806906/ /pubmed/20090941 http://dx.doi.org/10.1371/journal.pone.0008721 Text en Rosada et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Rosada, Rogério S. Moreira, Ana P. Frantz, Fabiani G. Puri, Raj K. Rahman, Aquilur Standiford, Theodore J. Zárate-Bladés, Carlos R. Silva, Célio L. Hogaboam, Cory M. Therapeutic Efficacy of Cintredekin Besudotox (IL13-PE38QQR) in Murine Lung Fibrosis Is Unaffected by Immunity to Pseudomonas aeruginosa Exotoxin A |
title | Therapeutic Efficacy of Cintredekin Besudotox (IL13-PE38QQR) in Murine Lung Fibrosis Is Unaffected by Immunity to Pseudomonas aeruginosa Exotoxin A |
title_full | Therapeutic Efficacy of Cintredekin Besudotox (IL13-PE38QQR) in Murine Lung Fibrosis Is Unaffected by Immunity to Pseudomonas aeruginosa Exotoxin A |
title_fullStr | Therapeutic Efficacy of Cintredekin Besudotox (IL13-PE38QQR) in Murine Lung Fibrosis Is Unaffected by Immunity to Pseudomonas aeruginosa Exotoxin A |
title_full_unstemmed | Therapeutic Efficacy of Cintredekin Besudotox (IL13-PE38QQR) in Murine Lung Fibrosis Is Unaffected by Immunity to Pseudomonas aeruginosa Exotoxin A |
title_short | Therapeutic Efficacy of Cintredekin Besudotox (IL13-PE38QQR) in Murine Lung Fibrosis Is Unaffected by Immunity to Pseudomonas aeruginosa Exotoxin A |
title_sort | therapeutic efficacy of cintredekin besudotox (il13-pe38qqr) in murine lung fibrosis is unaffected by immunity to pseudomonas aeruginosa exotoxin a |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806906/ https://www.ncbi.nlm.nih.gov/pubmed/20090941 http://dx.doi.org/10.1371/journal.pone.0008721 |
work_keys_str_mv | AT rosadarogerios therapeuticefficacyofcintredekinbesudotoxil13pe38qqrinmurinelungfibrosisisunaffectedbyimmunitytopseudomonasaeruginosaexotoxina AT moreiraanap therapeuticefficacyofcintredekinbesudotoxil13pe38qqrinmurinelungfibrosisisunaffectedbyimmunitytopseudomonasaeruginosaexotoxina AT frantzfabianig therapeuticefficacyofcintredekinbesudotoxil13pe38qqrinmurinelungfibrosisisunaffectedbyimmunitytopseudomonasaeruginosaexotoxina AT purirajk therapeuticefficacyofcintredekinbesudotoxil13pe38qqrinmurinelungfibrosisisunaffectedbyimmunitytopseudomonasaeruginosaexotoxina AT rahmanaquilur therapeuticefficacyofcintredekinbesudotoxil13pe38qqrinmurinelungfibrosisisunaffectedbyimmunitytopseudomonasaeruginosaexotoxina AT standifordtheodorej therapeuticefficacyofcintredekinbesudotoxil13pe38qqrinmurinelungfibrosisisunaffectedbyimmunitytopseudomonasaeruginosaexotoxina AT zaratebladescarlosr therapeuticefficacyofcintredekinbesudotoxil13pe38qqrinmurinelungfibrosisisunaffectedbyimmunitytopseudomonasaeruginosaexotoxina AT silvaceliol therapeuticefficacyofcintredekinbesudotoxil13pe38qqrinmurinelungfibrosisisunaffectedbyimmunitytopseudomonasaeruginosaexotoxina AT hogaboamcorym therapeuticefficacyofcintredekinbesudotoxil13pe38qqrinmurinelungfibrosisisunaffectedbyimmunitytopseudomonasaeruginosaexotoxina |